Macugen (Pegaptanib Sodium) Alone, Versus Macugen in Combination With PDT (Photodynamic Therapy) With Visudyne (Verteporfin) in Patients With Age-Related Macular Degeneration (AMD)

Part of paid clinical trials in Tucson, Arizona.

Sponsor
Eyetech Pharmaceuticals
Study ID
NCT00134667
Phase
PHASE4
Status
Terminated

Conditions

Eligibility Criteria

Sex
ALL
Age
50 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The purpose of the trial is to compare whether Macugen (pegaptanib sodium) in combination with PDT with Visudyne (verteporfin) is safe and effective in slowing down the leakage of fluid within the eye and thereby stabilizing or improving vision when compared to Macugen alone. Patients must be recently diagnosed with predominantly classic wet AMD and must be eligible for PDT.

Key Dates

First listed
Aug 25, 2005
Start date
Mar 31, 2005
Status verified
Jan 2007
Completion
Oct 31, 2008

Study Design

Enrollment
360 participants
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Locations (1)

FacilityCityStateZIPSite coordinators
Retina Centers, P.C., Northwest LocationTucsonArizona85704-5614-

Find similar trials in Tucson, AZ

By condition
Age-related macular degeneration
By specialty
OphthalmologyRetina
By research site
Retina Centers, P.C., Northwest Location· Tucson, AZ

Related Studies